Myeloma is the second most common blood cancer, but it is not a common cancer. An estimated 32,110 new patients will be diagnosed with myeloma in the United States in 2019, and men are diagnosed with the condition slightly more frequently than women. The mortality statistic in the U.S. i...
Multiple myeloma, malignant proliferation of cells within the bone marrow that usually occurs during middle age or later and increases in occurrence with age. Myelomas are slightly more common in males than in females and can affect any of the marrow-con
Multiple myeloma is a type ofcancerof the plasma cells (a type of white blood cells) of the bone marrow. Plasma cells are protein-making cells that normally produce the different kinds of antibodies of the disease-fighting immune system. In multiple myeloma, the plasma cells undergo a malignan...
Fujisawa M; Suehara Y; Fukumoto K;.Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years.Ann Hematol.2015.1-10Fujisawa M, Suehara Y, Fukumoto K, et al. Changes in survival rate of multiple myeloma after the ...
The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen (BCMA) is now widely approved in relapsed refractory
At present, the characteristics of double-hit multiple myeloma (DHMM) are unknown. We retrospectively analyzed the clinical data from 433 new diagnosed MM patients and found that DHMM have a higher β2-MG level and percentage of bone marrow plasma cell.
Multiple myeloma(MM) is a rare, malignant tumor of plasma cells that arises in the bone marrow and usually secretes large amounts ofimmunoglobulin. The finding of neoplastic plasma cells in blood samples or smears is rare.Dogsare affected more frequently than other species, butmultiple myelomahas...
The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma.
- 《Blood》 被引量: 401发表: 2010年 Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Genetic instability and cellular proliferation have been associated with aurora kinase expression in several cancer entities, including multiple myeloma. T... D Hose,T Rème,T...
Multiple myeloma (MM) is a disease in which abnormal plasma cells proliferate and secrete monoclonal immunoglobulin in the bone marrow. The main characteristic of plasma cells is the expression of the cell surface antigen syndecan-1 (CD138). However,